2024年5月19日 · ENV-101 (taladegib) is a potent, selective, orally available inhibitor of SMO,3-5 a key transmembrane protein of the Hh signaling pathway, that prevents the propagation of SHH signaling implicated in the pathogenesis and progression of IPF.

2024年5月19日 · Findings reinforce potential of ENV-101, a novel investigational Hedgehog (Hh) signaling pathway inhibitor, to be the first disease-modifying treatment for patients with idiopathic pulmonary fibrosis

2024年1月24日 · ENV-101 is an oral small molecule inhibitor of the Hedgehog (Hh) signaling pathway that offers a novel approach to treating the underlying pathologic mechanisms that cause fibrotic lung diseases..

ENV-101, A Novel Hedgehog Inhibitor, Increases Lung Function, and Reduces Lung Fibrosis in Patients With Idiopathic Pulmonary Fibrosis: Results From a Randomized, Double-blind, Placebo-controlled Phase 2 Trial

Endeavor BioMedicines’ investigational medicine ENV-101 is an Hh signaling pathway inhibitor. By binding to and inhibiting a key receptor in the Hh pathway, ENV-101 stops the abnormal accumulation of the myofibroblasts that cause fibrosis.

At the American Thoracic Society 2024 International Conference, Endeavor BioMedicines announced results from a completed Phase 2a clinical trial that demonstrate our lead investigational candidate, ENV-101, improved lung function and reversed key measures of lung fibrosis in patients with idiopathic pulmonary fibrosis (IPF).

2024年11月20日 · ENV-101 is a novel Hedgehog signaling pathway inhibitor that demonstrated potential in a Phase 2a trial to be the first disease-modifying treatment for IPF.

2024年5月20日 · ENV-101 is designed to block a cellular wound-healing pathway known as Hedgehog (Hh) that is abnormally activated in fibrotic lung diseases, such as IPF, and causes the continuous pathophysiologic buildup of scar tissue in the lungs..

2024年1月24日 · 临床阶段生物技术公司奋进生物医学（Endeavor BioMedicines）宣布成功完成其针对特发性肺纤维化（IPF）患者的ENV-101 2a期临床试验。 ENV-101是刺猬信号通路的口服小分子抑制剂，为治疗纤维化肺病提供了一种新方法。

This trial is a 6-month, randomized, double-blind, controlled, dose-ranging trial of ENV-101 in adult patients with idiopathic pulmonary fibrosis (IPF). Patients are allowed to continue treatment with approved standard of care (e.g., nintedanib, pirfenidone) during the trial.